Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262065 | 0.79 | CCR1 (0.40) | LPLLIPGADRA2AADRA2BADRA2C | |
| SCHEMBL111285 | 0.78 | LPL (0.49) | LPLLIPGP2RX7FFAR1DGAT1 | |
| SCHEMBL18840586 | 0.78 | LPL (0.34) | LPLLIPGADRA2AADRA2BADRA2C | |
| SCHEMBL25243329 | 0.78 | PTK2 (0.36) | LPLLIPGADRA2AADRA2BADRA2C | |
| SCHEMBL9940819 | 0.78 | LPL (0.34) | LPLLIPGF11P2RX7FFAR1 | |
| SCHEMBL442115 | 0.76 | ANPEP (0.32) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14718821 | 0.75 | SNCA (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23170259 | 0.75 | LPL (0.45) | LPLLIPGF11DGAT1 | |
| SCHEMBL27111331 | 0.75 | LPL (0.33) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14235345 | 0.74 | ALDH1A1 (0.39) | LPLLIPGDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3053925-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2813506-B1 | Tricyclic PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-2813506-A1 | Tricyclic PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | LPL 3263/4885LIPG 1906/4885CA1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.